The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
Zheng Li, Zheng Li, Yue Hu and 10 more
Frontiers in Oncology · 2022
doi:10.3389/fonc.2022.976143 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.